# Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

> **NCT01229865** · PHASE2 · COMPLETED · sponsor: **Vascular Biogenics Ltd. operating as VBL Therapeutics** · enrollment: 29 (actual)

## Conditions studied

- Differential Thyroid Cancer

## Interventions

- **DRUG:** VB-111

## Key facts

- **NCT ID:** NCT01229865
- **Lead sponsor:** Vascular Biogenics Ltd. operating as VBL Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2014-10
- **Final completion:** 2016-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2018-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01229865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01229865, "Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01229865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*